This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Video Lectures
2024 UCSF-UCLA PSMA Conference Videos
Patient Selection for Radioligand Therapy: Case Study Discussion - Amir Iravani & Evan Yu
April 11, 2024
Details
Operationalizing and Coordinating Lutetium-177 PSMA Treatment: Roles of a Multidisciplinary Prostate Cancer Team - Kristen Davis & Sarah Yenser Wood
March 20, 2024
Details
Current Perspectives: Theranostic Targets in Prostate Cancer - Hans David Ulmert
February 15, 2024
Details
Role of Radium-223 in the Setting of PSMA "Presentation" - Oliver Sartor
February 15, 2024
Details
Portfolio of Alpha and Beta Emitters to Improve Outcomes Presentation - Matthias Eiber
February 15, 2024
Details
Lutetium-177 PSMA Radioligand Therapy for Advanced Prostate Cancer: Reviewing the Pivotal VISION and TheraP Trials - Michael Morris
February 15, 2024
Details
Workflow Considerations from the Front Desk to Nursing Including the Supportive Care Idea: The UCLA/UCSF Experience "Presentation" - Linda Gardner & Amanda Morley
February 15, 2024
Details
PSMA-Directed Radioligand Therapy in Combination with Immunotherapy "Presentation" - Rahul Aggarwal
February 14, 2024
Details
Therapy Resistance and Combination Therapies "Presentation" - Johannes Czernin
February 14, 2024
Details
Evaluation of Theranostic Prostate Cancer Targets with Antibody Based Radiopharmaceuticals “Presentation” - Robert Flavell
February 14, 2024
Details
Role of Quantitative Dosimetry "Presentation" - Carlos Uribe
February 14, 2024
Details
Treatment Landscape of mCRPC "Presentation" - Matthew Rettig
February 13, 2024
Details
The PSMA and Androgen Receptors in Prostate Cancer "Presentation" - Louise Emmett
February 13, 2024
Details
SPECT Imaging Response with PSMA Radionuclide Therapy "Presentation" - Louise Emmett
February 13, 2024
Details
What is the Optimal Time for PSMA Radioligand Therapy? "Presentation" - Oliver Sartor
February 13, 2024
Details
Imaging Response to PSMA Radiopharmaceutical Therapy "Presentation" - Jeremie Calais
February 12, 2024
Details
Trials Evaluating the Impact of PSMA PET on Management and Outcomes “Presentation” - Amar Kishan
February 12, 2024
Details
Role of PSMA PET in CRPC Patients "Presentation" - Wolfgang Fendler
February 12, 2024
Details
PSMA PET Selection of Patients for PSMA Radiopharmaceutical Therapy “Presentation” - Jeremie Calais
February 12, 2024
Details
PSMAFore, SPLASH and ECLIPSE: Are They Different? "Presentation" - Thomas Hope, Michael Morris, & Oliver Sartor
February 12, 2024
Details
Role of MDT in BCR: Oligometastatic Disease "Presentation" - Amar Kishan
February 9, 2024
Details
PSMA PET Standardized Reporting "Presentation" - Matthias Eiber
February 9, 2024
Details
PSMA PET Appropriate Use Criteria "Presentation" - Michael Morris
February 9, 2024
Details
PSMA and RLT: The VISION and TheraP Trials "Presentation" - Michael Morris
February 9, 2024
Details
Clinical Impact of PSMA PET Prior to Prostatectomy “Presentation” - Robert Reiter
February 8, 2024
Details
PSMA-Targeted Radionuclide Therapy in the Pre- and Post-Chemotherapy Settings in Prostate Cancer - Louise Emmett
February 8, 2024
Details
Incorporating PSMA PET Into Radiotherapy Planning: Impact on Definitive Therapy "Presentation" - Nicholas Nickols
February 8, 2024
Details
ProPSMA Versus PreRP: Value of the Prospective Literature “Presentation” - Thomas Hope
February 8, 2024
Details
Patient Selection for PSMA Radioligand Therapy - Ephraim Parent
February 7, 2024
Details
Advancing Prostate Cancer Surgery with PSMA Imaging and Fluorescent Guidance "Presentation" - Peter Carroll
February 7, 2024
Details
PSMA PET & The Impact of the PRIMARY Trial "Presentation" - Louise Emmett
February 6, 2024
Details
Distinguishing True and False Positives on PSMA PET Scans "Presentation" - Courtney Lawhn Heath
February 5, 2024
Details
Examining Differences Between PSMA PET Imaging Agents "Presentation" - Wolfgang Fendler
February 5, 2024
Details
PSMA Targeted Imaging and Therapy in Prostate Cancer "Presentation" - Robert Flavell
February 5, 2024
Details
Access to Cutting-Edge Therapies and Clinical Trials in the VA- Matthew Rettig
February 2, 2024
Details
Radioligand Therapy's Role in Treating mCRPC - Oliver Sartor
February 2, 2024
Details
Highlights: UCLA/UCSF Inaugural PSMA PET and RLT Conference - Jeremie Calais
January 30, 2024
Details
PSMA PET and Radioligand Therapy: A Comprehensive Two-Day Conference by UCLA and UCSF - Jeremie Calais & Thomas Hope
October 11, 2023
Details
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free
